Tute Genomics has acquired key assets of Knome, a renowned human-genome interpretation company whose systems and services helped spearhead several of the greatest commercial advancements in modern human genetics.

Co-founded in 2007 by renowned geneticist and Harvard professor George Church, Knome has received national recognition and become a vanguard in fields such as personal genomics and genome research services. In addition to providing genome sequencing and interpretation to individuals such as Ozzy Osbourne and other high profile early adopters, the company’s most valuable technology is knoSYS, a best-in-class genome interpretation software platform. Now in its third generation, knoSYS has been transformed into the most sophisticated genome interpretation and clinical decision support system available.

Knome has received national recognition and become a vanguard in fields such as personal genomics and genome research services.Tute Genomics is integrating the knoSYS technology with its cloud-based genome informatics and clinical reporting platform to deliver the most comprehensive, flexible, scalable, and secure informatics solution for genome-guided medicine.

“Knome’s software is a testament to the extraordinary foresight and ingenuity of its scientists and engineers, as well as the remarkable amount of financial support the company has achieved over the years,” stated Reid Robison, MD, MBA, the CEO of Tute Genomics. “The result is a wealth of technology assets that are well-poised to tackle the bioinformatics challenges faced by healthcare, such as rapidly processing raw genome sequencing data, performing clinical interpretation of the data and generating actionable clinical reports.”

Knome’s knoSYS technology brings maximum value to the already robust genome informatics offerings at Tute, used by many of the top laboratories, hospitals, and genomics facilities across the world. Tute has also been integrated with third party tools such as LIMS for scalable sample information management, and EHR systems to bring genetic insights to point-of-care and help guide every medical decisions throughout a patient’s life.

Terms of the deal have not been disclosed.